Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2011 2
2012 1
2015 1
2016 3
2017 1
2018 1
2019 1
2020 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
Marathe CS, Pham H, Wu T, Trahair LG, Rigda RS, Buttfield MDM, Hatzinikolas S, Lange K, Rayner CK, Mari A, Horowitz M, Jones KL. Marathe CS, et al. Among authors: rigda rs. Diabetes Ther. 2022 Jun;13(6):1245-1249. doi: 10.1007/s13300-022-01258-4. Epub 2022 Apr 22. Diabetes Ther. 2022. PMID: 35460043 Free PMC article.
Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.
Jones KL, Huynh LQ, Hatzinikolas S, Rigda RS, Phillips LK, Pham HT, Marathe CS, Wu T, Malbert CH, Stevens JE, Lange K, Rayner CK, Horowitz M. Jones KL, et al. Among authors: rigda rs. Diabetes Obes Metab. 2020 May;22(5):788-797. doi: 10.1111/dom.13956. Epub 2020 Jan 28. Diabetes Obes Metab. 2020. PMID: 31903712 Clinical Trial.
Effects of intraduodenal administration of the artificial sweetener sucralose on blood pressure and superior mesenteric artery blood flow in healthy older subjects.
Pham HT, Stevens JE, Rigda RS, Phillips LK, Wu T, Hausken T, Soenen S, Visvanathan R, Rayner CK, Horowitz M, Jones KL. Pham HT, et al. Among authors: rigda rs. Am J Clin Nutr. 2018 Jul 1;108(1):156-162. doi: 10.1093/ajcn/nqy060. Am J Clin Nutr. 2018. PMID: 29878043 Free article. Clinical Trial.
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution.
Jalleh R, Pham H, Marathe CS, Wu T, Buttfield MD, Hatzinikolas S, Malbert CH, Rigda RS, Lange K, Trahair LG, Feinle-Bisset C, Rayner CK, Horowitz M, Jones KL. Jalleh R, et al. Among authors: rigda rs. Nutrients. 2020 Jul 1;12(7):1962. doi: 10.3390/nu12071962. Nutrients. 2020. PMID: 32630191 Free PMC article. Clinical Trial.
Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P, Checklin HL, Bound MJ, Rigda RS, Horowitz M, Jones KL, Rayner CK. Thazhath SS, et al. Among authors: rigda rs. Diab Vasc Dis Res. 2017 Jan;14(1):59-63. doi: 10.1177/1479164116666761. Epub 2016 Oct 20. Diab Vasc Dis Res. 2017. PMID: 27941058 Free article. Clinical Trial.
The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P, Checklin HL, Bound MJ, Rigda RS, Crouch B, Jones KL, Horowitz M, Rayner CK. Thazhath SS, et al. Among authors: rigda rs. Diabetes. 2016 Jan;65(1):269-75. doi: 10.2337/db15-0893. Epub 2015 Oct 15. Diabetes. 2016. PMID: 26470783 Clinical Trial.
13 results